PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice

Experimental Neurology

Volumn 232, Issue 2, 2011, Pages 333-338

  Brown, Jacquelyn A ^a   Xu, Jinbin ^a   Diggs Andrews, Kelly A ^a   Wozniak, David F ^a   Mach, Robert H ^a   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Behavior; Cyclic AMP; Dopamine; Neurofibromin; RAS

Indexed keywords

BUTACLAMOL; CYCLIC AMP; ETICLOPRIDE; METHYLPHENIDATE; MEVINOLIN; NOMIFENSINE; RACLOPRIDE C 11; RAS PROTEIN; ROLIPRAM; SELEGILINE; TETRABENAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; DRUG SCREENING; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PRIORITY JOURNAL;

ANIMALS; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARBON RADIOISOTOPES; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOPAMINERGIC NEURONS; DRUG EVALUATION, PRECLINICAL; METHYLPHENIDATE; MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; NEUROFIBROMATOSIS 1; NEUROPROTECTIVE AGENTS; POSITRON-EMISSION TOMOGRAPHY; PRESYNAPTIC TERMINALS; RACLOPRIDE; SELEGILINE;

EID: 80055004400     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.09.005     Document Type: Article

References (24)

1. Bajenaru M.L., Hernandez M.R., Perry A., Zhu Y., Parada L.F., Garbow J.R., Gutmann D.H. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 2003, 63:8573-8577.
2. Brown J.A., Emnett R.J., White C.R., Yuede C.M., Conyers S.B., O'Malley K.L., Wozniak D.F., Gutmann D.H. Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum. Mol. Genet. 2010, 19:4515-4528.
3. Brown J.A., Gianino S.M., Gutmann D.H. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J. Neurosci. 2010, 30:5579-5589.
4. Costa R.M., Federov N.B., Kogan J.H., Murphy G.G., Stern J., Ohno M., Kucherlapati R., Jacks T., Silva A.J. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002, 415:526-530.
5. Dasgupta B., Yi Y., Chen D.Y., Weber J.D., Gutmann D.H. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005, 65:2755-2760.
6. Fisone G., Hakansson K., Borgkvist A., Santini E. Signaling in the basal ganglia: postsynaptic and presynaptic mechanisms. Physiol. Behav. 2007, 92:8-14.
7. Frey K., Kilborn M., Robinson T. Reduced striatal vesicular monoamine transporters after neurtotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur. J. Pharmacol. 1997, 334:273-279.
8. Gutmann D.H., Aylsworth A., Carey J.C., Korf B., Marks J., Pyeritz R.E., Rubenstein A., Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51-57.
9. Hyman S.L., Shores A., North K.N. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005, 65:1037-1044.
10. Kim S., Salamon N., Jackson H.A., Bluml S., Panigraphy A. PET imaging in pediatric neuroradiology: current and future applications. Pediatr. Radiol. 2010, 40:82-96.
11. Krab L.C., de Goede-Bolder A., Aarsen F.K., Pluijm S.M., Bouman M.J., van der Geest J.N., Lequin M., Catsman C.E., Arts W.F., Kushner S.A., Silva A.J., de Zeeuw C.I., Moll H.A., Elgersma Y. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008, 300:287-294.
12. Li W., Cui Y., Kushner S.A., Brown R.A., Jentsch J.D., Frankland P.W., Cannon T.D., Silva A.J. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 2005, 15:1961-1967.
13. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl. Med. Biol. 2000, 27:661-670.
14. Rosa-Neto P., Lou H.C., Cumming P., Pryds O., Karrebaek H., Lunding J., Gjedde A. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage 2005, 25:868-876.
15. 3H]SCH 23390. Brain Res. 1986, 375:291-301.
16. Schiffer W.K., Volkow N.D., Fowler J.S., Alexoff D.L., Logan J., Dewey S.L. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 2006, 59:243-251.
17. Thanos P.K., Taintor N.B., Alexoff D., Vaska P., Logan J., Grandy D.K., Fang Y., Lee J.H., Fowler J.S., Volkow N.D., Rubinstein M. In vivo comparative imaging of dopamine D2 knockout and wild-type mice with (11)C-raclopride and microPET. J. Nucl. Med. 2002, 43:1570-1577.
18. Tong J., Hannan F., Zhu Y., Bernards A., Zhong Y. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat. Neurosci. 2002, 5:95-96.
19. Vallone D., Pignatelli M., Grammatikopoulos G., Ruocco L., Bozzi Y., Westphal H., Borrelli E., Sadile A.G. Activity, non-selective attention and emotionality in dopamine D2/D3 receptor knock-out mice. Behav. Brain Res. 2002, 130:141-148.
20. Volkow N.D., Wang G.J., Newcorn J., Telang F., Solanto M.V., Fowler J.S., Logan J., Ma Y., Schulz K., Pradhan K., Wong C., Swanson J.M. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 2007, 64:932-940.
21. 11C]raclopride in the human brain in response to methylphenidate. J. Nucl. Med. 1999, 40:1285-1291.
22. Warrington N.M., Woerner B.M., Dagninakatte G.C., Dasgupta B., Perry A., Gutmann D.H., Rubin J.B. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res. 2007, 67:8588-8595.
23. Xu J., Chu W., Tu Z., Jones L.A., Luedtke R.R., Perlmutter J.S., Mintun M.A., Mach R.H. (3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization. Synapse 2009, 63:717-728.
24. 3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen. Synapse 2010, 64:449-459.